Results 191 to 200 of about 2,565,028 (307)

Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy. [PDF]

Biomolecules
Lizama-Muñoz A, Plaza-Diaz J.
europepmc   +1 more source

Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug. [PDF]

Front Chem, 2023
Li W, Li M, Huang Q, He X, Shen C, Hou X, Xue F, Deng Z, Luo Y.   +8 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma. [PDF]

Cancers (Basel)
Flauto F, De Martino MC, Vitiello C, Pivonello R, Colao A, Damiano V.   +5 more
europepmc   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

A self-directed Trojanbot-enzymatic nanobot in neutrobot for active target therapy of glioblastoma. [PDF]

Nat Commun
Gao Y, Mao M, Li Y, Xuan M, Wu Y, He Q.
europepmc   +1 more source

Cell Therapy as Target Therapy against Colon Cancer Stem Cells. [PDF]

Int J Mol Sci, 2023
Garza Treviño EN, Quiroz Reyes AG, Rojas Murillo JA, de la Garza Kalife DA, Delgado Gonzalez P, Islas JF, Estrada Rodriguez AE, Gonzalez Villarreal CA.   +7 more
europepmc   +1 more source

Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma

Molecular Oncology, EarlyView.
The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...
Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen   +5 more
wiley   +1 more source

Fibroblast-like synoviocytes mediate the generation of soluble PD-1 in an MMP-9-dependent manner: a novel target therapy for rheumatoid arthritis. [PDF]

Front Immunol
Yang C, Ma M, Yu K, Wang Y, Zhang Y, Shen Y, Wang J, Wang X, Luo L, Zhao Y.   +9 more
europepmc   +1 more source

Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? [PDF]

Front Immunol, 2023
Yang Y, He X, Rojas M, Leung PSC, Gao L.
europepmc   +1 more source